User profiles for Kyle R. Brimacombe

Kyle R Brimacombe

Verified email at mail.nih.gov
Cited by 4940

Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19

RT Eastman, JS Roth, KR Brimacombe… - ACS central …, 2020 - ACS Publications
The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven
the biomedical community to action—to uncover and develop antiviral interventions. One …

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

…, N Southall, MJ Walsh, KR Brimacombe… - Nature chemical …, 2012 - nature.com
Cancer cells engage in a metabolic program to enhance biosynthesis and support cell
proliferation. The regulatory properties of pyruvate kinase M2 (PKM2) influence altered glucose …

A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate

ME Pacold, KR Brimacombe, SH Chan… - Nature chemical …, 2016 - nature.com
Serine is both a proteinogenic amino acid and the source of one-carbon units essential for
de novo purine and deoxythymidine synthesis. In the canonical pathway of glucose-derived …

Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

…, DM Schlatzer, H Tang, R Papoian, KR Brimacombe… - Nature, 2015 - nature.com
Multiple sclerosis involves an aberrant autoimmune response and progressive failure of
remyelination in the central nervous system. Prevention of neural degeneration and subsequent …

Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors

…, S Nimmagadda, K Sudini, KR Brimacombe… - ACS chemical …, 2016 - ACS Publications
Loss of function mutations in Kelch-like ECH Associated Protein 1 (KEAP1), or gain-of-function
mutations in nuclear factor erythroid 2-related factor 2 (NRF2), are common in non-small …

[HTML][HTML] Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells

H Sarin, AS Kanevsky, H Wu, KR Brimacombe… - Journal of translational …, 2008 - Springer
Background Effective transvascular delivery of nanoparticle-based chemotherapeutics across
the blood-brain tumor barrier of malignant gliomas remains a challenge. This is due to our …

Synthesis and structure–activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein

MD Hall, KR Brimacombe, MS Varonka… - Journal of medicinal …, 2011 - ACS Publications
Cancer multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters
presents a significant unresolved clinical challenge. One strategy to resolve MDR is to …

Discovery and optimization of potent, cell-active pyrazole-based inhibitors of lactate dehydrogenase (LDH)

G Rai, KR Brimacombe, BT Mott, DJ Urban… - Journal of medicinal …, 2017 - ACS Publications
We report the discovery and medicinal chemistry optimization of a novel series of pyrazole-based
inhibitors of human lactate dehydrogenase (LDH). Utilization of a quantitative high-…

[HTML][HTML] An OpenData portal to share COVID-19 drug repurposing data in real time

KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang… - BioRxiv, 2020 - ncbi.nlm.nih.gov
The National Center for Advancing Translational Sciences (NCATS) has developed an online
open science data portal for its COVID-19 drug repurposing campaign–named OpenData–…

[HTML][HTML] Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays

DJ Urban, NJ Martinez, MI Davis, KR Brimacombe… - Scientific reports, 2017 - nature.com
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that are
mutated in a variety of cancers to confer a gain-of-function activity resulting in the accumulation …